U.S. Supreme Court rebuffs AbbVie appeal in patent fight involving AndroGel drug
The U.S. Supreme Court on Monday declined to hear AbbVie Inc''s (ABBV.N) challenge to a lower court''s decision that it violated federal antitrust law by pursuing a "sham" patent complaint against rival Perrigo Co (PRGO.N) over AbbVie''s blockbuster testosterone replacement drug AndroGel.
U.S. Supreme Court rebuffs AbbVie appeal in patent fight involving AndroGel drug
The U.S. Supreme Court on Monday declined to hear AbbVie Inc''s (ABBV.N) challenge to a lower court''s decision that it violated federal antitrust law by pursuing a "sham" patent complaint against rival Perrigo Co (PRGO.N) over AbbVie''s blockbuster testosterone replacement drug AndroGel.